SCHEMBL21189193

SCHEMBL21189193

O=C(N[C@H]1CCOc2c(C(=O)Nc3ccc(F)c(Cl)c3)ccc(F)c21)OCCN1CCCC1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C19 P33261 1/20 0.47
SMN1; SMN2 Q16637 3/20 0.44
MCHR1 Q99705 1/20 0.37
CHRM3 P20309 3/20 0.37
AADAT Q8N5Z0 1/20 0.37
RAB9A P51151 1/20 0.37
MAPT P10636 5/20 0.36
NPSR1 Q6W5P4 2/20 0.36
CNR1 P21554 1/20 0.36
GPR35 Q9HC97 1/20 0.36
GPR55 Q9Y2T6 1/20 0.36
LMNA P02545 3/20 0.36
ENPP2 Q13822 1/20 0.36
ALDH1A1 P00352 2/20 0.36
POLB P06746 1/20 0.36
TP53 P04637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21189300 0.91 SMN1; SMN2 (0.38) MEN1KMT2ACYP1A2CYP3A4CYP2C19
SCHEMBL26597510 0.88 MEN1 (0.50) MEN1KMT2ACYP1A2CYP3A4CYP2C19
SCHEMBL21189537 0.83 MAPT (0.43) MEN1KMT2ASMN1; SMN2RAB9AMAPT
SCHEMBL21189276 0.81 NPC1 (0.46) MEN1KMT2ASMN1; SMN2RAB9AMAPT
SCHEMBL21189195 0.81 NPC1 (0.46) MEN1KMT2ASMN1; SMN2RAB9AMAPT
SCHEMBL21189275 0.81 NPC1 (0.46) MEN1KMT2ASMN1; SMN2RAB9AMAPT
SCHEMBL21189190 0.80 KMT2A (0.36) MEN1KMT2ASMN1; SMN2RAB9AMAPT
SCHEMBL21189306 0.80 KMT2A (0.36) MEN1KMT2ASMN1; SMN2RAB9AMAPT
SCHEMBL19973907 0.80 IDO1 (0.40) MEN1KMT2ASMN1; SMN2CHRM3MAPT
SCHEMBL19973909 0.80 IDO1 (0.40) MEN1KMT2ASMN1; SMN2CHRM3MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11001564-B2 Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same ARBUTUS BIOPHARMA CORPORATION (CA) 2021-05-11 US disclosed
US-20190225593-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (CA) 2019-07-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225593-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME CBX8, HAVCR2, HCCS MEN1 1933/4885KMT2A 155/4885CYP1A2 530/4885
US-11001564-B2 Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same CBX8, HAVCR2, HCCS MEN1 1933/4885KMT2A 155/4885CYP1A2 530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.